Pharma Event ROI: How to Choose the Right B2B Platform

In recent years, the value of industry events for pharmaceutical companies is becoming a more practical and more measurable question. Before committing a budget, teams want to understand what an event can realistically deliver: access to the right audience, relevant meetings, useful market insights and outcomes that can support live business priorities. This article looks at how pharma teams approach event ROI today, why it often remains difficult to prove, and why AUTOMA+ 2026 offers a format built around more predictable and measurable participation value.

In pharma, participation in industry events is judged increasingly through the lens of return. Budgets are tighter, calendars are fuller and internal scrutiny is stronger. That changes the way companies decide where to invest time and money. An event in 2026 is expected to fulfill clear business goals: meeting the right partners, opening conversations with decision-makers, benchmarking priorities or gathering ideas relevant to live projects.

Seen this way, attendance starts to look less like a routine marketing activity and more like a business development decision that needs a visible outcome. The more pressure there is on budgets and priorities, the more carefully companies assess what an event can realistically deliver.

What Makes Pharma Event ROI Difficult to Measure

The challenge with ROI is simple: the cost is easy to calculate, while the outcome often is not. Travel, accommodation, participation fees and team time are visible from the start, but the value created during an event is much harder to define. A company may leave with a positive overall impression and still struggle afterwards to explain what was actually gained, which conversations mattered most and whether participation helped move any real business priority forward.

This usually happens when the format makes results difficult to control. The audience may be broad without being specific enough. Networking may happen, yet too much of it depends on chance. Teams may arrive without clearly defined objectives or discover that the specialists they most need to meet are not present. Sometimes the programme is simply too general to connect with the issues companies are actively working through. In that situation, attendance may feel useful in theory while remaining difficult to justify in measurable terms.

That is why pharma companies have become more selective. They look more closely at audience quality, topic relevance, access to decision-makers and the structure of the networking format itself. Participation is easier to justify when it offers the right mix of relevant peers, focused discussions and a setting that helps companies have the conversations they actually came for.

How Teams Can Evaluate ROI Before the Event

ROI does not have to be measured only after the event is over. In many cases, the potential value of participation can be assessed in advance. The most useful way to approach it is to define priorities early: the team’s objectives, the types of companies that matter most, the roles that are essential to meet, the number of relevant conversations that would make participation worthwhile and the issues that should be discussed.

A large gathering may look impressive on paper, but scale does not guarantee relevance. What matters far more is whether it creates the conditions for meaningful conversations with the right people: decision-makers, potential partners, technology users, service providers or peers facing similar operational challenges. The programme matters too. Sessions become more valuable when they connect directly to current priorities and give teams something useful to take back into ongoing projects, internal discussions or future collaboration plans.

A practical way to assess an industry event is to use a simple 5-steps checklist. Before committing budget, companies can ask:

• Do we have clear business goals for participating? What are they?

• Are the right companies and decision-makers likely to be in the room?

• Does the programme reflect the issues our team is actively working on?

• Is there a structured meeting format that increases the chances of relevant conversations?

• Can we define in advance what success would look like in numbers: meetings, follow-ups, opportunities or insights?

Potential ROI often becomes clearer when expected outcomes can be mapped in advance. If the format makes it easier to identify relevant contacts, plan meetings and enter discussions linked to real business needs, the return is already more tangible before the event begins. The strongest outcomes rarely come from footfall alone. They tend to grow out of relevant conversations that continue afterwards through follow-ups, partnerships, new opportunities or better-informed decisions.

AUTOMA+ 2026 as a Practical Choice for Measurable Pharma Event ROI

This is where AUTOMA+ 2026 becomes especially relevant. Its format makes participation easier to connect with concrete business goals. Instead of relying on broad exposure or chance encounters, the Congress brings together a curated audience of pharma professionals: decision-makers and specialists working in automation, digitalisation, manufacturing, quality, engineering and related functions. That matters because value is much easier to assess when the people in the room already match the conversations your team needs to have.

“By talking with such a highly diverse audience you come up with new ideas, you see new applications and new opportunities. I think that’s the biggest advantage of AUTOMA+ – you can think outside the box and meet people who you would never expect to meet”, – Harald Schnidar, CEO of SCARLETRED Holding GmbH (AUTOMA+ 2026 Platinum Sponsor).

The same principle shapes the structure of the Congress. AUTOMA+ 2026 is built around practical exchange: focused B2B meetings, access to relevant stakeholders and a programme shaped by real implementation cases in pharma automation and digitalisation. 

“AUTOMA+ Congress is important for pharma professionals because here we're able to connect, able to meet new customers, new people and build up a network”, - Andreas Nicklas, Founder & Managing Director of anic GmbH (AUTOMA+ 2025 Gold Sponsor).

For companies taking a pragmatic approach, AUTOMA+ creates a far more predictable basis for ROI. It becomes possible to estimate the likely number of relevant discussions, judge how closely the programme reflects current priorities and understand how participation may support follow-up actions afterwards.

To support that evaluation, we have also created a practical ROI calculator that helps participants estimate the potential return from taking part in AUTOMA+ 2026 before the Congress even begins. If you would like to assess the expected results for your company, contact us to request access to the calculator and explore the value of participating in AUTOMA+ 2026.

FAQ

What is AUTOMA+ 2026?

AUTOMA+ 2026 is the Pharmaceutical Automation and Digitalisation Congress, bringing together senior decision-makers and specialists from pharmaceutical manufacturers, CMOs, CDMOs, equipment suppliers and technology providers to address the practical challenges of automation, digitalisation and manufacturing excellence in pharma. The programme covers MES, SCADA, LIMS, AI in manufacturing, GMP compliance, quality systems and digital infrastructure for regulated environments.

When and where does AUTOMA+ 2026 take place?

AUTOMA+ 2026 takes place on 16-17 November 2026 in Zurich, Switzerland, across two days of sessions, roundtables, an exhibition and structured B2B meetings with participants from the pharmaceutical value chain.

Who attends AUTOMA+ 2026?

AUTOMA+ 2026 is attended by C-level executives, heads of automation, digitalisation leads, manufacturing directors, quality and engineering specialists from pharmaceutical operators, CMOs and CDMOs, alongside equipment manufacturers, system integrators and technology providers serving the regulated pharma environment. The congress operates on a closed-door model to ensure a focused professional environment of end-users, licensors and solution providers.

How do companies participate in AUTOMA+ 2026?

Companies participate in AUTOMA+ 2026 as delegates, sponsors, exhibitors or speakers. Participation details are available on request.

How can pharma companies measure ROI from industry events?

Pharma companies can measure event ROI most effectively by defining expected outcomes before participation begins rather than assessing results only afterwards. The key indicators to set in advance are the number of relevant meetings with decision-makers, alignment between the programme and live business priorities, quality of the audience relative to the team's target contacts and the number of follow-up actions generated. ROI becomes easier to justify when the event format offers structured B2B meetings and a curated audience, because both the likely outcomes and the cost of participation can be estimated before the event.

What makes a pharma industry event worth attending in 2026?

A pharma industry event is worth attending in 2026 when it offers three things together: the right audience of decision-makers and technical specialists in automation, digitalisation and manufacturing; a programme built around current implementation challenges rather than general trends; and a meeting format that makes relevant conversations predictable rather than dependent on chance. Scale alone is not a reliable indicator of value - a smaller, curated event with structured access to relevant peers and session content tied to live projects typically delivers more measurable outcomes than a large general event.